Multimodal Prehabilitation To Improve The Clinical Outcomes Of Frail Elderly Patients With Gastric Cancer

Sponsor
The Affiliated Hospital of Qingdao University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05352802
Collaborator
Shandong Provincial Hospital (Other), Qilu Hospital of Shandong University (Other), Qianfoshan Hospital (Other), Yantai Yuhuangding Hospital (Other), Shandong Jining No.1 People's Hospital (Other), Weifang Medical University (Other), Weifang People's Hospital (Other), Dongying People's Hospital (Other), Weihai Municipal Hospital (Other), Weihai Central Hospital (Other), Rizhao People's Hospital (Other), Liaocheng People's Hospital (Other)
368
1
2
48
7.7

Study Details

Study Description

Brief Summary

The GISSG+2201 study was launched by Shandong Gastrointestinal Surgery Study Group (GISSG). The intention is to establish a multimodal prehabilitation protocol in frail elderly patients who undergo gastric cancer radical surgery, explore the feasibility and effectiveness of the measures and evaluate the effect of program on short-term clinical outcome, recovery index and the long-term tumor-related outcome.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Multimodal prehabilitation program
  • Behavioral: ERAS protocol
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
368 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Multimodal Prehabilitation To Improve The Clinical Outcomes Of Frail Elderly Patients With Gastric Cancer: A Multicenter Randomized Controlled Trial
Anticipated Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
May 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Prehabilitation group

The prehabilitation group received multimodal prehabilitation combined with ERAS before the gastrectomy.

Behavioral: Multimodal prehabilitation program
Multimodal prehabilitation programs have adopted planned, structural, repetitive and purposeful approach that includes elements of exercise, nutritional and psychological.

Behavioral: ERAS protocol
The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.

Active Comparator: ERAS group

The ERAS group patients were treated according to the ERAS pathway.

Behavioral: ERAS protocol
The core content is to adopt a series of optimized measures performed during the perioperative period on the basis of evidence-based medical findings to reduce the physiological and psychological stress of patients and to accelerate their recovery.

Outcome Measures

Primary Outcome Measures

  1. The incidence and severity of postoperative complications [Postoperative (≤30 days after surgery)]

    Major postoperative complications of patients with Gastrointestinal malignancy included gastrointestinal complication, surgical site complication, respiratory complication, cardiovascular complication, thromboembolic complication, urinary complication and other complications. The severity of complications was recorded and classified according to Clavien-Dindo classification score.

Secondary Outcome Measures

  1. Cardio-pulmonary function and physical capacity [Baseline (T0), Post-intervention (up to 2 weeks), and POD 30(30 days after surgery)]

    The 6-minute walk test (6MWT) can be used to measure exercise capacity to reflect cardio-pulmonary function.

  2. Quality of life (QoL). [Baseline (T0), Post-intervention (up to 2 weeks), and POD 30(30 days after surgery)]

    QoL comprises patient-reported outcomes (PRO) of physical symptoms and psychosocial health status. Quality of Life Questionnaire (QLQ) C30 is sensitive tool for measuring individual performance status. Each index score ranges from 1 to 4, with higher scores indicating higher risk.

  3. Detection of immune and inflammatory indicators [Baseline (T0), Post-intervention (up to 2 weeks), and POD 30(30 days after surgery)]

    Interleukin, Tumor necrosis factor and C-reactive protein serum concentrations

  4. The postoperative other observation parameters [Postoperative (≤30 days after surgery)]

    Postoperative pain severity, postoperative delirium severity and occurrence, first exhaust and defecation, ureteral catheter removal, abdominal drainage tubes removal, postoperative hospital stay, hospitalization costs, 30-day all-cause mortality and 30-day hospital readmission rate.

  5. Oncological outcomes [3 years]

    3-year recurrence-free survival (RFS) rate and 3-year overall survival (OS) rate.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Aged 65-85 years;

  2. Karnofsky performance score ≥70 or Eastern Cooperative Oncology Group (ECOG) performance status score ≤2;

  3. G8 score ≤14;

  4. Endoscopic biopsies were pathologically confirmed as gastric adenocarcinoma;

  5. Patients with cT1-4aN0-3M0 by endoscopy, imaging evaluations of CT and MRI, and possibility of gastric resection;

  6. Received general anesthesia or combined spinal-epidural anesthesia (Surgery was performed by either laparotomy, laparoscopy or robotic-assisted laparoscopic);

  7. Date of surgery ≥2 weeks from baseline (T0) assessment;

  8. Physical conditions could meet the requirements of exercise training, and no severe concomitant disease;

  9. All subjects had to be willing and able to comply with study protocol and were informed adequately that they maintained the right to drop out of the study at any time.

Exclusion Criteria:
  1. Patients with uncontrolled seizure disorders, central nervous system diseases and mental disorders;

  2. End-stage cardiac insufficiency (LVEF<30% or NYHA class IV), liver cirrhosis (Child-Pugh classification C), End-stage renal failure (receives chronic dialysis), or ASA grade IV;

  3. Cerebral bleeding or infarction (within 6 months);

  4. Patients with recurrent infection diseases or serious concomitant disease;

  5. Patients who require synchronous surgery due to other illness;

  6. Patients who required emergency surgery within an emergency setting (obstruction, bleeding, perforation);

  7. Patients who are participating in any other clinical trials.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Gastrointestinal Surgery, Qingdao University Affiliated Hospital Qingdao Shandong China 266000

Sponsors and Collaborators

  • The Affiliated Hospital of Qingdao University
  • Shandong Provincial Hospital
  • Qilu Hospital of Shandong University
  • Qianfoshan Hospital
  • Yantai Yuhuangding Hospital
  • Shandong Jining No.1 People's Hospital
  • Weifang Medical University
  • Weifang People's Hospital
  • Dongying People's Hospital
  • Weihai Municipal Hospital
  • Weihai Central Hospital
  • Rizhao People's Hospital
  • Liaocheng People's Hospital

Investigators

  • Study Director: Yanbing Zhou, MD, The Affiliated Hospital of Qingdao University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
The Affiliated Hospital of Qingdao University
ClinicalTrials.gov Identifier:
NCT05352802
Other Study ID Numbers:
  • GISSG+2201
First Posted:
Apr 29, 2022
Last Update Posted:
Apr 29, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by The Affiliated Hospital of Qingdao University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 29, 2022